Jury Finds Monsanto’s Roundup Responsible for Man’s Cancer

A San Francisco court levels $289 Million in damages against the pesticide maker.

Sukanya Charuchandra
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: ©ISTOCK, AMYKERK

ASuperior Court jury in California on August 10 granted Dewayne Johnson $289 million in damages from Monsanto for its Roundup weed killer having caused his cancer. This is the first of more than 5,000 lawsuits Monsanto faces for its glyphosate-based weed killers. Johnson's case, filed in 2016, was fast-tracked because of the speed at which his non-Hodgkin lymphoma was progressing, according to Reuters.

The San Francisco jury took three days to deliver its verdict. Jury members agreed the company should have labeled Roundup as hazardous. One of Johnson’s lawyers, Brent Wisner, says in a statement that Monsanto knew “glyphosate and specifically Roundup could cause cancer,” according to company records.

After the trial, Scott Partridge, Monsanto’s vice president for global strategy, said the documents had been “taken completely out of context,” according to The Guardian. He added that the trial doesn't alter “the four-plus decades of safe use ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Sukanya Charuchandra

    Sukanya Charuchandra

    Originally from Mumbai, Sukanya Charuchandra is a freelance science writer based out of wherever her travels take her. She holds master’s degrees in Science Journalism and Biotechnology. You can read her work at sukanyacharuchandra.com.

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide